section name header

Pronunciation ⬇

zi-PRA-si-done audio

Indications ⬆ ⬇

BEERS REMS

Action ⬆ ⬇

Therapeutic Effects:

Pharmacokinetics ⬆ ⬇

Absorption: 60% absorbed following oral administration; 100% absorbed from IM sites.

Distribution: Unknown.

Protein Binding: 99%; potential for drug interactions due to drug displacement is minimal.

Metabolism/Excretion: 99% metabolized by the liver; <1% excreted unchanged in urine.

Half-life: PO — 7 hr; IM — 2–5 hr.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: orthostatic hypotension, QT interval prolongation.

Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME (SJS), rash, urticaria.

Endo: galactorrhea, hyperglycemia, hyperlipidemia, weight gain.

GI: constipation, diarrhea, nausea, dysphagia.

GU: amenorrhea, impotence.

Hemat: AGRANULOCYTOSIS, leukopenia, neutropenia.

Neuro: NEUROLEPTIC MALIGNANT SYNDROME, seizures, dizziness, drowsiness, restlessness, extrapyramidal reactions, syncope, tardive dyskinesia.

Resp: cough, rhinorrhea.

Interactions ⬆ ⬇

Drug-Drug:

Route/Dosage ⬆ ⬇

Schizophrenia

Acute Manic or Mixed Episodes Associated with Bipolar I Disorder

Maintenance Treatment of Bipolar I Disorder (as adjunct to lithium or valproate)

Implementation ⬆ ⬇

US Brand Names ⬆ ⬇

Geodon

Canadian Brand Names ⬆ ⬇

Zeldox

Classifications ⬆ ⬇

Therapeutic Classification: antipsychotics

Pharmacologic Classification: piperazine derivatives

Availability ⬆ ⬇

(Generic available)

Time/Action Profile ⬆ ⬇

(blood levels)

ROUTEONSETPEAKDURATION
POwithin hrs1–3 days†unknown
IMrapid60 minunknown

†Steady state achieved following continuous use.

Assessment ⬆ ⬇

Lab Test Considerations:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

Code ⬆

NDC Code*